econd quarter of 2010, primarily due to higher non-GAAP profit from operations, which was partially offset by lower other income.
Diluted earnings per ADS were $0.18, which compares with $0.26 in the second quarter of 2010.
Non-GAAP diluted earnings per ADS were $0.25, which compares with $0.28 in the second quarter of 2010.
Financial Position As of June 30, 2011, the Company had cash and cash equivalents of $41.6 million and short term debt of $0.8 million. During the quarter, capital expenditures totaled $11.0 million, including $5.5 million related to the purchase of a 68,000 square foot new lab and office building which replaced the original 36,000 square foot facility in Chengdu. The purchased lab and office building allows us to reduce overall expenditures and improve our earnings over time. With a strong balance sheet and sound financial position, the Company is well positioned to make targeted investments when opportunities arise.
Full Year 2011 GuidanceThe Company reconfirms its guidance for full year 2011. The Company expects: Net revenues to be approximately $111.1 – $115.6 million, which represents growth of approximately 23.0% – 28.0% compared with full year 2010. Non-GAAP gross margin to be approximately 33.5% – 35.5%, which is within the same range as non-GAAP gross margin of 34.5% in 2010. Capital expenditure to be $28 - $32 million, including $6 million rolling payment lag impact carried forward from 2010.
This reflects the Company's current view and is subject to change.
Conference CallShangPharma will host a conference call and live webcast at 8am New York time on August 22, 2011 (8pm Beijing time on August 22, 2011). A PowerPoint presentation accompanying the prepared remarks will be available on the Company's website shortly before the call.
The dial-in details
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Related biology technology :1
|SOURCE ShangPharma Corporation|
Copyright©2010 PR Newswire.
All rights reserved
. ShangPharma Corporation Named a Top Ten Chinese Outsourcing Enterprise2
. ShangPharma Announces First Quarter 2011 Results3
. ShangPharma Corp. to Announce Fourth Quarter and Full Year 2010 Financial Results on March 15, 20114
. Stem Cell Assurance, Inc. Announces Change of Name to BioRestorative Therapies, Inc.5
. Syndax Pharmaceuticals Announces Issuance of EU Patent for Entinostat6
. Regeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA7
. ACMG Announces New Online Live Learning Center: Will Bring Genetics and Genomics Education to Varied Health Professionals8
. Neurologix Announces Second Quarter 2011 Financial Results9
. Bion Announces New U.S. Patent for Phosphorus Removal10
. ViaCyte Announces Executive Management Changes11
. NeoStem Announces the Receipt of Over $1,700,000 in DOD Funding for its VSEL™ Technology Being Developed to Treat Osteoporosis